BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung
View original at globenewswire.comBioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung BioNTech treibt Onkologiestrategie mit dem Fokus auf zwei tumorübergreifende (Pan-Tumor)-Programme sowie Kombinationsansätze weiter voran, um das gesamte Spektrum von Krebserkrankungen vom frühen bis zum späten S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
BioNTech expects no positive net income for FY 2025
80% confidence2025 CapEx expected to be €200-250M, reduced from previous guidance of €250-350M
80% confidence2025 revenue guidance is €2,600-2,800M
80% confidencePumitamig showed encouraging anti-tumor activity, positive PFS trend, controlled safety profile, and low discontinuation rate in ES-SCLC Phase 2 trial
80% confidenceROSETTA Breast-01 Phase 3 trial for TNBC will start by end of 2025
80% confidence2025 R&D costs expected to be €2,000-2,200M, reduced from previous guidance of €2,600-2,800M
80% confidenceTrastuzumab Pamirtecan BLA filing planned for 2026 pending FDA feedback
80% confidenceAutogene Cevumeran showed strong durable immune responses up to 1.5 years post-treatment with broad immune response correlated with extended PFS
80% confidenceBNT111 demonstrated deep durable antitumor responses with statistically significant improvement in ORR vs historical control
80% confidence2025 SG&A costs expected to be €550-650M, reduced from previous guidance of €650-750M
80% confidence
Data points we hold from this source
| BioNTech SE · outstanding shares | 240455450 shares |
| BioNTech SE · r and d costs | 564.8 million_EUR |
| BioNTech SE · sg and a costs | 148.5 million_EUR |